Mark Edward Williams, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Failure, Chronic | 25 | 2020 | 2457 | 3.500 |
Why?
|
| Renal Dialysis | 18 | 2020 | 1786 | 2.730 |
Why?
|
| Diabetic Nephropathies | 15 | 2013 | 973 | 2.500 |
Why?
|
| Nephrology | 4 | 2020 | 263 | 1.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 8 | 2019 | 3432 | 0.930 |
Why?
|
| Hyperglycemia | 4 | 2014 | 1368 | 0.740 |
Why?
|
| Blood Glucose | 8 | 2019 | 6346 | 0.630 |
Why?
|
| Blood Component Removal | 3 | 2013 | 132 | 0.600 |
Why?
|
| Hypoglycemia | 3 | 2013 | 881 | 0.560 |
Why?
|
| Renal Agents | 2 | 2006 | 30 | 0.520 |
Why?
|
| Diabetes Complications | 2 | 2014 | 1317 | 0.520 |
Why?
|
| Plasma Exchange | 2 | 2013 | 158 | 0.520 |
Why?
|
| Pyridoxamine | 4 | 2007 | 10 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2014 | 2239 | 0.480 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2019 | 12075 | 0.470 |
Why?
|
| Diabetes Mellitus | 5 | 2015 | 5816 | 0.460 |
Why?
|
| Hypoglycemic Agents | 5 | 2019 | 3069 | 0.440 |
Why?
|
| Glycemic Index | 1 | 2015 | 393 | 0.420 |
Why?
|
| Hospital Departments | 1 | 2013 | 134 | 0.410 |
Why?
|
| Risk Adjustment | 2 | 2013 | 600 | 0.400 |
Why?
|
| Kidney Diseases | 4 | 2013 | 2083 | 0.400 |
Why?
|
| Physician Executives | 1 | 2013 | 133 | 0.400 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 130 | 0.390 |
Why?
|
| Minerals | 1 | 2009 | 283 | 0.290 |
Why?
|
| Hypertension | 3 | 2013 | 8499 | 0.270 |
Why?
|
| Antibodies | 1 | 2013 | 2420 | 0.250 |
Why?
|
| Vitamin B Complex | 1 | 2007 | 297 | 0.250 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2009 | 409 | 0.250 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 557 | 0.240 |
Why?
|
| Drugs, Investigational | 1 | 2006 | 212 | 0.220 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2008 | 515 | 0.220 |
Why?
|
| Drug Utilization Review | 1 | 2004 | 248 | 0.210 |
Why?
|
| Physicians | 1 | 2020 | 4580 | 0.200 |
Why?
|
| Insurance Benefits | 1 | 2004 | 188 | 0.200 |
Why?
|
| Proteinuria | 1 | 2005 | 594 | 0.200 |
Why?
|
| Dietetics | 1 | 2002 | 34 | 0.200 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2004 | 346 | 0.190 |
Why?
|
| Medically Uninsured | 1 | 2007 | 836 | 0.190 |
Why?
|
| Living Donors | 1 | 2006 | 638 | 0.190 |
Why?
|
| Polypharmacy | 1 | 2004 | 305 | 0.190 |
Why?
|
| Diabetic Angiopathies | 1 | 2006 | 802 | 0.180 |
Why?
|
| Enzyme Inhibitors | 3 | 2005 | 3709 | 0.170 |
Why?
|
| Conflict of Interest | 1 | 2005 | 548 | 0.170 |
Why?
|
| Humans | 48 | 2020 | 758406 | 0.170 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 2167 | 0.170 |
Why?
|
| Informed Consent | 1 | 2006 | 1003 | 0.160 |
Why?
|
| Blood Pressure | 2 | 2013 | 8451 | 0.160 |
Why?
|
| Receptors, Cell Surface | 1 | 2008 | 2825 | 0.160 |
Why?
|
| Pre-Eclampsia | 1 | 2008 | 1227 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2009 | 2560 | 0.150 |
Why?
|
| Albuminuria | 3 | 2011 | 650 | 0.150 |
Why?
|
| Insulin Infusion Systems | 1 | 2019 | 217 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2008 | 3997 | 0.150 |
Why?
|
| Palliative Care | 1 | 2012 | 3570 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2006 | 2189 | 0.140 |
Why?
|
| Risk Factors | 10 | 2020 | 73809 | 0.130 |
Why?
|
| Geriatric Assessment | 1 | 2004 | 1404 | 0.130 |
Why?
|
| Hyperparathyroidism, Secondary | 2 | 2009 | 125 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2006 | 1150 | 0.130 |
Why?
|
| Maleimides | 2 | 2006 | 113 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2003 | 1780 | 0.120 |
Why?
|
| Disease Management | 3 | 2013 | 2500 | 0.120 |
Why?
|
| Aged | 17 | 2015 | 168218 | 0.120 |
Why?
|
| Medicare | 2 | 2004 | 6741 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2007 | 2495 | 0.120 |
Why?
|
| Stents | 1 | 2006 | 3162 | 0.110 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2013 | 59 | 0.110 |
Why?
|
| Centrifugation | 1 | 2013 | 122 | 0.110 |
Why?
|
| Guanidines | 2 | 2004 | 192 | 0.110 |
Why?
|
| Internet | 1 | 2006 | 3082 | 0.110 |
Why?
|
| Hemodialysis Units, Hospital | 1 | 2013 | 22 | 0.110 |
Why?
|
| Activities of Daily Living | 1 | 2003 | 2414 | 0.110 |
Why?
|
| Education, Nursing, Continuing | 1 | 2013 | 70 | 0.100 |
Why?
|
| Glycosaminoglycans | 2 | 2006 | 605 | 0.100 |
Why?
|
| Metabolic Clearance Rate | 1 | 2013 | 361 | 0.100 |
Why?
|
| Plasmapheresis | 1 | 2013 | 206 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 5 | 2013 | 2154 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2005 | 3433 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2005 | 3242 | 0.100 |
Why?
|
| Disease Progression | 5 | 2010 | 13468 | 0.090 |
Why?
|
| Health Personnel | 1 | 2005 | 3312 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 3992 | 0.090 |
Why?
|
| Protein Kinase C | 2 | 2006 | 1199 | 0.090 |
Why?
|
| Kidney Function Tests | 1 | 2013 | 677 | 0.090 |
Why?
|
| Patient Selection | 3 | 2012 | 4244 | 0.090 |
Why?
|
| Kidney Transplantation | 3 | 2012 | 4217 | 0.090 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2010 | 91 | 0.090 |
Why?
|
| Parathyroid Hormone | 2 | 2009 | 1797 | 0.090 |
Why?
|
| Peritoneal Dialysis | 1 | 2010 | 157 | 0.080 |
Why?
|
| Aging | 2 | 2010 | 8650 | 0.080 |
Why?
|
| Social Adjustment | 1 | 2011 | 632 | 0.080 |
Why?
|
| Renin-Angiotensin System | 1 | 2013 | 733 | 0.080 |
Why?
|
| Treatment Outcome | 8 | 2013 | 64378 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 1159 | 0.080 |
Why?
|
| Inpatients | 1 | 2019 | 2551 | 0.070 |
Why?
|
| Renal Replacement Therapy | 1 | 2010 | 281 | 0.070 |
Why?
|
| Health Services for the Aged | 1 | 2010 | 259 | 0.070 |
Why?
|
| Kidney | 2 | 2013 | 7016 | 0.070 |
Why?
|
| Age Factors | 3 | 2013 | 18358 | 0.070 |
Why?
|
| Serum Albumin | 1 | 2010 | 673 | 0.070 |
Why?
|
| Indoles | 2 | 2006 | 1828 | 0.070 |
Why?
|
| Interdisciplinary Communication | 1 | 2013 | 931 | 0.070 |
Why?
|
| Health Priorities | 1 | 2010 | 375 | 0.070 |
Why?
|
| North America | 1 | 2010 | 1276 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2013 | 989 | 0.070 |
Why?
|
| Drug Monitoring | 1 | 2013 | 960 | 0.070 |
Why?
|
| Compensation and Redress | 1 | 2007 | 66 | 0.070 |
Why?
|
| Critical Pathways | 1 | 2010 | 473 | 0.070 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 6362 | 0.070 |
Why?
|
| Survival Rate | 3 | 2011 | 12721 | 0.070 |
Why?
|
| Middle Aged | 11 | 2015 | 219568 | 0.060 |
Why?
|
| Creatine | 1 | 2007 | 426 | 0.060 |
Why?
|
| Geriatrics | 1 | 2010 | 387 | 0.060 |
Why?
|
| Malaria, Falciparum | 1 | 2013 | 1076 | 0.060 |
Why?
|
| Female | 16 | 2015 | 390323 | 0.060 |
Why?
|
| Longevity | 1 | 2012 | 1050 | 0.060 |
Why?
|
| Insulin | 1 | 2019 | 6578 | 0.060 |
Why?
|
| Male | 15 | 2015 | 358747 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3425 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2014 | 15225 | 0.060 |
Why?
|
| Hypertension, Renal | 1 | 2004 | 135 | 0.060 |
Why?
|
| Emigration and Immigration | 1 | 2007 | 394 | 0.060 |
Why?
|
| Tissue and Organ Procurement | 1 | 2012 | 943 | 0.060 |
Why?
|
| Ergocalciferols | 1 | 2004 | 110 | 0.050 |
Why?
|
| Case Management | 1 | 2005 | 273 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 6493 | 0.050 |
Why?
|
| Boston | 2 | 2013 | 9304 | 0.050 |
Why?
|
| Diabetic Neuropathies | 1 | 2006 | 405 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2012 | 2311 | 0.050 |
Why?
|
| Acceleration | 1 | 2003 | 189 | 0.050 |
Why?
|
| Nutritional Status | 1 | 2010 | 1607 | 0.050 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 2016 | 0.050 |
Why?
|
| United States | 7 | 2013 | 72136 | 0.050 |
Why?
|
| Prognosis | 3 | 2011 | 29557 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2013 | 3561 | 0.050 |
Why?
|
| Protein-Energy Malnutrition | 1 | 2002 | 188 | 0.050 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2002 | 362 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2010 | 9650 | 0.040 |
Why?
|
| Quality of Life | 2 | 2012 | 13285 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2015 | 41256 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2011 | 1831 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 12440 | 0.040 |
Why?
|
| Insulin Resistance | 1 | 2013 | 3941 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2008 | 6354 | 0.040 |
Why?
|
| Decision Making | 1 | 2012 | 3915 | 0.040 |
Why?
|
| Nutrition Assessment | 1 | 2002 | 726 | 0.040 |
Why?
|
| Models, Animal | 1 | 2005 | 2112 | 0.040 |
Why?
|
| Adult | 8 | 2011 | 219935 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1673 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 4809 | 0.040 |
Why?
|
| Double-Blind Method | 3 | 2007 | 12262 | 0.040 |
Why?
|
| Thiazoles | 1 | 2005 | 1510 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2010 | 2359 | 0.040 |
Why?
|
| Mass Screening | 1 | 2013 | 5427 | 0.030 |
Why?
|
| Risk | 1 | 2008 | 9599 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 3671 | 0.030 |
Why?
|
| Bone Density | 1 | 2009 | 3533 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 10146 | 0.030 |
Why?
|
| Drug Costs | 1 | 2004 | 1178 | 0.030 |
Why?
|
| Walking | 1 | 2003 | 1188 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 5404 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2003 | 1878 | 0.030 |
Why?
|
| Sepsis | 1 | 2008 | 2587 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2010 | 4775 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2013 | 80168 | 0.030 |
Why?
|
| Massachusetts | 1 | 2007 | 8823 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2006 | 9267 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 9160 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7378 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 15651 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 12951 | 0.030 |
Why?
|
| Insurance Coverage | 1 | 2004 | 1933 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2011 | 39059 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2010 | 23884 | 0.020 |
Why?
|
| Time Factors | 2 | 2010 | 39872 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2002 | 2307 | 0.020 |
Why?
|
| Incidence | 1 | 2010 | 21272 | 0.020 |
Why?
|
| Immune System Diseases | 1 | 2013 | 258 | 0.020 |
Why?
|
| Health Status | 1 | 2004 | 4071 | 0.020 |
Why?
|
| Societies, Medical | 2 | 2013 | 3891 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2006 | 5629 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2013 | 496 | 0.020 |
Why?
|
| Delivery of Health Care | 1 | 2007 | 5331 | 0.020 |
Why?
|
| Hospitalization | 1 | 2008 | 10652 | 0.020 |
Why?
|
| Animals | 3 | 2006 | 167768 | 0.020 |
Why?
|
| Models, Biological | 1 | 2004 | 9460 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2010 | 449 | 0.020 |
Why?
|
| Cadaver | 1 | 2012 | 1345 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2010 | 58683 | 0.020 |
Why?
|
| Pregnancy | 1 | 2008 | 29742 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2010 | 785 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 2210 | 0.020 |
Why?
|
| Adolescent | 2 | 2011 | 87892 | 0.010 |
Why?
|
| Phosphorus | 1 | 2004 | 335 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 4839 | 0.010 |
Why?
|
| Fellowships and Scholarships | 1 | 2010 | 1115 | 0.010 |
Why?
|
| Blood Pressure Determination | 1 | 2003 | 634 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 7985 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 7818 | 0.010 |
Why?
|
| Logistic Models | 1 | 2010 | 13276 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2011 | 3364 | 0.010 |
Why?
|
| Registries | 1 | 2010 | 8175 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 10748 | 0.010 |
Why?
|
| Calcium | 1 | 2004 | 5721 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 58808 | 0.000 |
Why?
|
| Prospective Studies | 1 | 2003 | 54137 | 0.000 |
Why?
|